Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer (PROSELICA)

Clinical Trial ID NCT01308580

PubWeight™ 15.55^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01308580

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Overview of the latest treatments for castration-resistant prostate cancer.	Nat Rev Urol	2013	1.12
2	Castration-resistant prostate cancer: latest evidence and therapeutic implications.	Ther Adv Med Oncol	2014	1.11
3	Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.	Prostate Cancer Prostatic Dis	2011	1.08
4	The changing landscape in the treatment of metastatic castration-resistant prostate cancer.	Ther Adv Med Oncol	2013	0.97
5	Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.	Ther Adv Urol	2014	0.96
6	Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.	P T	2012	0.92
7	Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.	Oncologist	2011	0.90
8	Chemotherapy and its evolving role in the management of advanced prostate cancer.	Asian J Androl	2014	0.88
9	Preclinical profile of cabazitaxel.	Drug Des Devel Ther	2014	0.85
10	The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer.	Ther Adv Urol	2014	0.83
11	Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.	Clin Med Insights Oncol	2011	0.81
12	Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.	Clin Med Insights Oncol	2012	0.80
13	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer.	Clin Med Insights Oncol	2016	0.80
14	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.	Cancer Biol Ther	2012	0.79
15	Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy.	J Clin Immunol	2011	0.78
16	Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.	Clin Genitourin Cancer	2012	0.77
17	Management of metastatic castration-resistant prostate cancer.	Eur Urol Rev	2011	0.75
18	Castrate-resistant prostate cancer: postdocetaxel management.	Curr Opin Urol	2013	0.75
19	Open clinical uro-oncology trials in Canada.	Can J Urol	2012	0.75